InvestorsHub Logo
Followers 260
Posts 19732
Boards Moderated 0
Alias Born 10/03/2004

Re: noretreat post# 54833

Tuesday, 10/11/2011 1:02:27 PM

Tuesday, October 11, 2011 1:02:27 PM

Post# of 146248

Thanks. Some thoughtful comparisons. Do you think the fact that NNVC is microscopic and has no other products will impair their negotiating position?


I don't think so. Once human safety and efficacy are established I think the negotiations will be competitive. Currently, Big Pharma is cash rich and very conservative and risk averse. No one wants to be the goat for talking Big Pharma into completing trials on an expensive turd, but at some point no one will want to be the biopharma equivalent of the publisher's agent who turned down J.K. Rowling and Harry Potter. It's one thing to lose in negotiations because the CFO won't go that high, it's quite another to reject what in hindsight will be a major career gaffe.

CTIX isn't having trouble with starting trials due to funding; quite the contrary, they are delayed briefly adding indications before the INDA is filed. Yesterday's PR signaled that. Dana Farber is picking up the tab for Phase 1/2a trials and CTIX only has to supply the drug and delivery mechanism.

When the time comes for expended trials and more money, it will be there, even if NNVC has to dust off those last $30 million in shares in the shelf registration.

I hope they do, but they will need a partner for marketing, packaging and distribution, IMO.

Are you really taking advice from a Muppet doc?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News